International review of cell and molecular biology最新文献_第6页

Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients. 健康与疾病中的免疫检查点生物学：免疫检查点生物学与癌症患者的自身免疫。

3区生物学

International review of cell and molecular biology Pub Date : 2024-01-01 Epub Date: 2023-05-24 DOI: 10.1016/bs.ircmb.2023.04.003

Pierre Van Mol, Elena Donders, Diether Lambrechts, Els Wauters

引用次数: 0

Novel technologies for applying immune checkpoint blockers. 应用免疫检查点阻断剂的新技术。

3区生物学

International review of cell and molecular biology Pub Date : 2024-01-01 Epub Date: 2023-03-30 DOI: 10.1016/bs.ircmb.2023.03.003

Robin Maximilian Awad, Karine Breckpot

引用次数: 0

Epigenome editing in cancer: Advances and challenges for potential therapeutic options. 癌症中的表观基因组编辑：潜在治疗方案的进展与挑战。

3区生物学

International review of cell and molecular biology Pub Date : 2024-01-01 Epub Date: 2023-11-21 DOI: 10.1016/bs.ircmb.2023.10.001

Seung-Won Lee, Connor Mitchell Frankston, Jungsun Kim

引用次数: 0

Epigenetic alterations in AML: Deregulated functions leading to new therapeutic options. 急性髓细胞性白血病的表观遗传学改变：功能失调带来新的治疗方案。

3区生物学

International review of cell and molecular biology Pub Date : 2024-01-01 Epub Date: 2024-07-09 DOI: 10.1016/bs.ircmb.2024.06.003

Kourosh Hayatigolkhatmi, Riccardo Valzelli, Oualid El Menna, Saverio Minucci

{"title":"Epigenetic alterations in AML: Deregulated functions leading to new therapeutic options.","authors":"Kourosh Hayatigolkhatmi, Riccardo Valzelli, Oualid El Menna, Saverio Minucci","doi":"10.1016/bs.ircmb.2024.06.003","DOIUrl":"https://doi.org/10.1016/bs.ircmb.2024.06.003","url":null,"abstract":"Acute myeloid leukemia (AML) results in disruption of the hematopoietic differentiation process. Crucial progress has been made, and new therapeutic strategies for AML have been developed. Induction chemotherapy, however, remains the main option for the majority of AML patients. Epigenetic dysregulation plays a central role in AML pathogenesis, supporting leukemogenesis and maintenance of leukemic stem cells. Here, we provide an overview of the intricate interplay of altered epigenetic mechanisms, including DNA methylation, histone modifications, and chromatin remodeling, in AML development. We explore the role of epigenetic regulators, such as DNMTs, HMTs, KDMs, and HDACs, in mediating gene expression patterns pushing towards leukemic cell transformation. Additionally, we discuss the impact of cytogenetic lesions on epigenomic remodeling and the potential of targeting epigenetic vulnerabilities as a therapeutic strategy. Understanding the epigenetic landscape of AML offers insights into novel therapeutic avenues, including epigenetic modifiers and particularly their use in combination therapies, to improve treatment outcomes and overcome drug resistance.","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":"387 ","pages":"27-75"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiation for inflammatory breast cancer: Updates. 炎症性乳腺癌的放射治疗：更新。

3区生物学

International review of cell and molecular biology Pub Date : 2024-01-01 Epub Date: 2023-10-19 DOI: 10.1016/bs.ircmb.2023.10.004

Michael C Stauder

引用次数: 0

Chemotherapy to potentiate the radiation-induced immune response. 化疗以增强辐射诱导的免疫反应。

3区生物学

International review of cell and molecular biology Pub Date : 2023-01-01 DOI: 10.1016/bs.ircmb.2023.01.004

Benoît Lecoester, Mylène Wespiser, Amélie Marguier, Céline Mirjolet, Jihane Boustani, Olivier Adotévi

引用次数: 0

Knowing the myeloid-derived suppressor cells: Another enemy of sarcomas patients. 了解髓源性抑制细胞:肉瘤患者的另一个敌人。

3区生物学

International review of cell and molecular biology Pub Date : 2023-01-01 DOI: 10.1016/bs.ircmb.2022.11.003

Daniel J García-Domínguez, Víctor Sánchez-Margalet, Luis de la Cruz-Merino, Lourdes Hontecillas-Prieto

{"title":"Knowing the myeloid-derived suppressor cells: Another enemy of sarcomas patients.","authors":"Daniel J García-Domínguez, Víctor Sánchez-Margalet, Luis de la Cruz-Merino, Lourdes Hontecillas-Prieto","doi":"10.1016/bs.ircmb.2022.11.003","DOIUrl":"https://doi.org/10.1016/bs.ircmb.2022.11.003","url":null,"abstract":"Sarcomas are heterogeneous and aggressive malignant tumors with variable responses to current standard treatments being usually incurable for those patients with metastatic and unresectable diseases. The lack of curative strategies has led to develop new therapies in the treatment of sarcomas where the role of immune system is an evolving field. Most sarcomas often exhibit an immunosuppressive microenvironment, which reduces their capacity to trigger an immune response. Therefore, sarcomas are broadly considered as an \"immune cold\" tumor, although some studies have described a great immune heterogeneity across sarcoma subtypes. Sarcoma cells, like other tumors, evade their immune destruction through a variety of mechanisms, including expansion and recruitment of myeloid derived suppressor cells (MDSCs). MDSCs are immature myeloid cells that have been correlated with a reduction of the therapeutic efficacy, including immunotherapy, tumor progression and worst prognosis. Consequently, different strategies have been developed in recent years to target MDSCs in cancer treatments. This chapter discusses the role of MDSCs in sarcomas and their current potential as a therapeutic target in these malignancies.","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":"375 ","pages":"93-116"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9506631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myeloid-derived suppressor cells in head and neck squamous cell carcinoma. 头颈部鳞状细胞癌中的髓源性抑制细胞。

3区生物学

International review of cell and molecular biology Pub Date : 2023-01-01 DOI: 10.1016/bs.ircmb.2022.11.002

Jing-Yu He, Fang-Yi Huo, Hong-Chao Tang, Bing Liu, Lin-Lin Bu

{"title":"Myeloid-derived suppressor cells in head and neck squamous cell carcinoma.","authors":"Jing-Yu He, Fang-Yi Huo, Hong-Chao Tang, Bing Liu, Lin-Lin Bu","doi":"10.1016/bs.ircmb.2022.11.002","DOIUrl":"https://doi.org/10.1016/bs.ircmb.2022.11.002","url":null,"abstract":"Myeloid-derived suppressor cells (MDSCs), which originated from hematopoietic stem cells, are heterogeneous population of cells that have different differentiation patterns and widely presented in tumor microenvironment. For tumor research, myeloid suppressor cells have received extensive attention since their discovery due to their specific immunosuppressive properties, and the mechanisms of immunosuppression and therapeutic approaches for MDSCs have been investigated in a variety of different types of malignancies. To improve the efficacy of treatment for head and neck squamous cell carcinoma (HNSCC), a disease with a high occurrence, immunotherapy has gradually emerged in after traditional surgery and subsequent radiotherapy and chemotherapy, and has made some progress. In this review, we introduced the mechanisms on the development, differentiation, and elimination of MDSCs and provided a detailed overview of the mechanisms behind the immunosuppressive properties of MDSCs. We summarized the recent researches on MDSCs in HNSCC, especially for targeting-MDSCs therapy and combination with other types of therapy such as immune checkpoint blockade (ICB). Furthermore, we looked at drug delivery patterns and collected the current diverse drug delivery systems for the improvement that contributed to therapy against MDSCs in HNSCC. Most importantly, we made possible outlooks for the future research priorities, which provide a basis for further study on the clinical significance and therapeutic value of MDSCs in HNSCC.","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":"375 ","pages":"33-92"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9506633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Non-coding RNAs in the epigenetic landscape of cutaneous T-cell lymphoma. 非编码rna在皮肤t细胞淋巴瘤的表观遗传景观。

3区生物学

International review of cell and molecular biology Pub Date : 2023-01-01 DOI: 10.1016/bs.ircmb.2023.04.004

Monaza Adeeb, Lubna Therachiyil, Safwan Moton, Joerg Buddenkotte, Majid Ali Alam, Shahab Uddin, Martin Steinhoff, Aamir Ahmad

{"title":"Non-coding RNAs in the epigenetic landscape of cutaneous T-cell lymphoma.","authors":"Monaza Adeeb, Lubna Therachiyil, Safwan Moton, Joerg Buddenkotte, Majid Ali Alam, Shahab Uddin, Martin Steinhoff, Aamir Ahmad","doi":"10.1016/bs.ircmb.2023.04.004","DOIUrl":"https://doi.org/10.1016/bs.ircmb.2023.04.004","url":null,"abstract":"Cutaneous T-cell lymphoma (CTCL) is a type of cancer that affects skin, and is characterized by abnormal T-cells in the skin. Epigenetic changes have been found to play a significant role in the development and progression of CTCL. Recently, non-coding RNAs (ncRNAs), such as microRNAs and long non-coding RNAs, have been identified as key players in the regulation of gene expression in CTCL. These ncRNAs can alter the expression of genes involved in cell growth, differentiation, and apoptosis, leading to the development and progression of CTCL. In this review, we summarize the current understanding of the role of ncRNAs in CTCL, including their involvement in DNA methylation, and other biological processes. We also discuss the types of ncRNAs, their role as oncogenic or tumor suppressive, and their putative use as diagnostic and prognostic biomarkers, based on the emerging evidence from laboratory-based as well as patients-based studies. Moreover, we also present the potential targets and pathways affected by ncRNAs. A better understanding of the complex epigenetic landscape of CTCL, including the role of ncRNAs, has the potential to lead to the development of novel targeted therapies for this disease.","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":"380 ","pages":"149-171"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10159656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rational selection of an ideal oncolytic virus to address current limitations in clinical translation. 合理选择理想的溶瘤病毒以解决目前临床转译的局限性。

3区生物学

International review of cell and molecular biology Pub Date : 2023-01-01 DOI: 10.1016/bs.ircmb.2023.03.004

Rupsa Basu, Chad M Moles

引用次数: 0